Last Updated: Dec 22, 2021
On Wednesday, the FDA issued an emergency use authorization for Pfizer’s Paxlovid, an antiviral pill for oral use, to treat mild-to-moderate COVID-19 in adults and children ages 12 years of age and older. Patients with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death can receive the prescription. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.
Read more.
Thank you for the comment! Your comment must be approved first
You've already submitted a review for this item
Thank you! Your review has been submitted successfully
Login to be able to comment
Comment cannot be empty
Rating is required
You typed the code incorrectly. Please try again